Liquid Biopsy - Cancer
Liquid biopsies are typically conducted with blood as the sample type, and are used to identify cancer biomarkers in circulating tumor DNA (ctDNA) or on circulating tumor cells (CTCs), which are the most commonly evaluated indicators or drivers of cancer development. Doctors may use liquid biopsies to help design cancer treatment plans, to evaluate how well treatment is working, or to determine if a prior cancer condition has recurred. The ability to take multiple samples of blood may help doctors understand what kind of molecular changes are taking place over time in a patient’s tumor.
THE IVYGENE TEST
The IvyGene test may confirm the presence of multiple cancers, as early as stage 1. The IvyGene test is a highly accurate, simple blood draw that has been validated for confirming the presence breast, colon, liver, and lung cancer. Other cancers may result in an elevated IvyGene test.
According to IVYGENE: CONFIRMING CANCER EARLY - More than 600,000 people will die from cancer in 2019. More than 1 million individuals will be diagnosed with new cancer cases during that same time. By confirming the presence of multiple cancers early, the chances of survival increase by more than 50%. THE SCIENCE - The technology behind the IvyGene test has been published in several major publications, including Nature Materials and the Proceedings of the National Academy of Sciences. The technology has been commercially developed by the Laboratory for Advanced Medicine, whose goal is to turn cancer from a life-threatening disease into a manageable illness. The IvyGene Core Test confirms the presence of multiple cancers, as early as stage 1. The Core Test has been validated for confirming the presence of breast, colon, liver, and lung cancer.
Circulating tumor cells (CTCs) are cells that have detached from a primary tumor and circulate in the bloodstream. CTCs may travel to other areas and create new tumors in different tissues or organs (metastases). Elevated CTCs at any time in the course of clinical treatment of metastic breast cancer are indicators of progression.
ctDNA stands for circulating tumor DNA. These fragments of non-cellular mutated DNA can find their way into blood through either apoptosis or necrosis of the solid tumor tissue. ctDNA can also be generated from circulating tumor cells (CTCs) that are released by a tumor into the blood stream, followed by degradation within the blood stream and a release of DNA contents.
The capture and detection of CTCs may have important prognostic and therapeutic implications because detection of tumor cells may have clinical utility in risk stratification in early cancer, in early detection of relapse, and in monitoring response to treatment. The presence of tumor cells circulating in the blood has been associated with shortened survival from various solid tumor cancers.
A prognostic test may indicate the outcome and course of a disease. A predictive test suggests likely response to a particular therapy. Information about the presence and number of CTCs has prognostic value. Biomarker status results indicate whether a patient is a candidate for tailored drug therapy and are therefore predictive.
Biocept’s testing platform is not designed to screen for cancer. It is intended to provide information to clinicians about the presence of CTCs, ctDNA, and other specific biomarkers, such as proteins and amplifications, from the CTCs. These results assist physicians in understanding the status of the disease and in making decisions on current and future therapy. Treatments for metastatic cancer have advanced over the past years, but diagnostic tools for selecting the appropriate pharmacologic agent have lagged. Liquid biopsy is an advanced tool available now for your physician. Biocept’s liquid biopsy is performed on a simple blood sample.
Liquid biopsy testing can be performed before, during, and after your therapy. You and your doctor should discuss the test, the frequency of the test, and what is appropriate for your unique situation.
Most health plans cover our testing and it may be determined that the patient may have a balance (co-pay, deductible, or co-insurance) based upon the individual benefit design of the patients policy. In addition, some health plans reimburse the patient directly for the laboratory services when the laboratory is an out-of-network provider.
If I am having chemo or radiation treatment, when should my blood be drawn for a liquid biopsy test? We recommend that you and your physician wait two weeks after treatment to draw blood and send to Biocept. Most treatment cycles are 3-4 weeks apart.
Both IVYGENE and Biocept’s testing is conducted in our office. Please call to schedule an appointment: 401-921-5934